Original Publication Date: 27 January, 2017
Publication / Source: Future Medicinal Chemistry
Authors: Kronenberger T, Asse Jr LR, Wrenger C et al.
Aim: FabI is a key enzyme in the fatty acid metabolism of Gram-positive bacteria such as Staphylococcus aureus and is an established drug target for known antibiotics such as triclosan. However, due to increasing antibacterial resistance, there is an urgent demand for new drug discovery. Recently, aminopyridine derivatives have been proposed as promising competitive inhibitors of FabI. Methods: In the present study, holographic structure–activity relationship (HQSAR) analyses were employed for determining structural contributions of a series containing 105 FabI inhibitors.